16/4 an

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as thirst class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22318311850.

Burton Rodney

Type or print name

Signature

June 2, 2005

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

BETH ANNE PIPER

Examiner: R. Cook

APPLICATION NO: 09/460,920

FILED: DECEMBER 14, 1999

FOR: METHOD FOR TREATING DIABETES

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the reference cited on the attached form PTO-1449.

This reference was cited in a search report in a corresponding Ukrainian application. A copy of this reference and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).



Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Burton Rodney

Reg. No. 22,076

Attomey for Applicant

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: June 2, 2005

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. LA0046a CIP-1 APPLICATION NO. 09/460,920 APPLICANT Beth Anne Piper FILING DATE

Group

6 2005 g					DECEMBER 14, 1999			1614		
RADEMARY			U.S.	PATENT DOCUMENTS						
XAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	ASS SUBCL	ASS F	ILING D		
	AA									
	AB									
00	AC									
	AD									
	AE									
	AF									
	AG									
	АН									
	Al									
	AJ									
	AK									
· · · · · · · · · · · · · · · · · · ·	AL							•		
			FOREIG	N PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	ISLATI N		
	АМ									
	AN									
	AO									
	AP									
	AQ					,				
		OTHER DOC	JMENTS (Including Author, Title, Date, Perti	nent pages, E	Etc.)				
	AR	R. Lupi, et al., "Effects from isolated human p	of glibencla ancreatic is	amide and metformin (alone of lets", Acta Diabetol. 34: 46-48	r in combin	ation) on ins	ulin erle	ease		
	AS					,				
	АТ						. 1**			
EXAMIN	ED			DATE CONSIDERED	•					

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.